Grifols SA (GRFS) AI Stock Analysis

• Market Cap: $8.12B
• Dividend Yield: 1.56%
• Average Volume (3M): 710.42K
• Price to Earnings (P/E): 15.0
• Beta (1Y): 0.92
• Revenue Growth: 9.45%
• EPS Growth: 167.00%
• Country: US
• Employees: 23,833
• Sector: N/A
• Sector Strength: N/A
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.22
• Shares Outstanding: 261,425,100
• 10 Day Avg. Volume: 573,323
• 30 Day Avg. Volume: 710,421
• PEG Ratio: 0.20
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.68
• P/FCF Ratio: 9.20
• Enterprise Value/Market Cap: 2.49
• Enterprise Value/Revenue: 2.69
• Enterprise Value/Gross Profit: 6.81
• Enterprise Value/Ebitda: 13.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: $10.00 ▲(13.90% Upside)

Grifols SA's strong financial performance and positive earnings call sentiment are the most significant factors driving the score. While technical indicators suggest potential bearish momentum, the company's robust revenue growth and operational efficiency provide a solid foundation. Valuation is moderate, offering neither a significant discount nor premium.

Grifols SA Business Overview & Revenue Model

Company Description

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in the production of plasma-derived therapies and biopharmaceuticals. The company operates primarily in the biotechnology sector, focusing on the development, manufacturing, and marketing of innovative products for the treatment of various medical conditions, including hemophilia, immunodeficiencies, and neurological disorders. Grifols' core products include immunoglobulins, albumin, and clotting factor concentrates, which are derived from human plasma and used in critical care settings and for patients with chronic diseases.

How the Company Makes Money

Grifols generates revenue primarily through the sale of plasma-derived therapies and other biopharmaceutical products. The company operates a vertically integrated business model, which involves collecting human plasma through its network of donation centers, processing it into therapeutics, and distributing these products to hospitals and healthcare providers worldwide. Key revenue streams include the sale of immunoglobulins, albumin, and clotting factor concentrates, which are essential for treating patients with specific medical needs. Additionally, Grifols has established significant partnerships with healthcare institutions and plasma collection organizations that enhance its supply chain and expand its market reach. The company's ongoing investment in research and development, along with a commitment to innovation, further contributes to its earnings by allowing it to introduce new products and improve existing therapies.

Grifols SA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Grifols SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Negative. The current price of 8.78 is below the 20-day moving average (MA) of 9.15, below the 50-day MA of 8.90, and below the 200-day MA of 8.94, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 45.64 is Neutral, neither overbought nor oversold. The STOCH value of 27.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRFS.

Grifols SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
GILD	78 Outperform	$153.93B	19.22	40.53%	2.52%	2.76%	6407.19%
AMGN	77 Outperform	$177.14B	25.43	81.71%	3.00%	11.03%	65.22%
GSK	77 Outperform	$101.52B	14.29	35.62%	3.41%	5.97%	128.66%
SNY	75 Outperform	$116.05B	11.91	8.39%	4.58%	-9.32%	120.62%
BMY	73 Outperform	$116.08B	19.25	33.84%	4.84%	1.26%	―
GRFS	72 Outperform	$8.12B	15.05	6.93%	1.56%	9.45%	167.00%

Grifols SA Corporate Events

Grifols Adjusts Board Secretariat Roles Effective January 1, 2026

On January 8, 2026, Grifols, S.A. announced that its Board of Directors unanimously approved changes to the Board’s non-member officer roles, effective January 1, 2026. Laura de la Cruz Galán has been appointed Secretary non-member of the Board of Directors, replacing Núria Martín Barnés, who in turn has been appointed Vice-secretary non-member of the Board, replacing de la Cruz Galán. The reshuffling, endorsed by the Appointments and Remuneration Committee, fine-tunes the company’s board support structure but does not alter the composition of the board itself, suggesting a continuity-focused adjustment to corporate governance rather than a strategic shift with immediate operational impact.

The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.

Grifols Achieves EMA Certification for Egyptian Plasma Operations

On December 11, 2025, Grifols, S.A. announced that the European Medicines Agency (EMA) granted a Certificate of Compliance for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), a joint venture with Egypt’s National Service Projects Organization. This certification, following a rigorous quality inspection, allows GEPD to manufacture and commercialize plasma products throughout Europe and other regions adhering to EMA legislation. This milestone positions Egypt as the first country in Africa and the Middle East with a fully integrated plasma collection and processing system meeting international standards, marking a significant achievement for Grifols in the global plasma industry.

The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.

Grifols Reports Strong Q3 2025 Financial Performance with Biopharma Growth

On November 4, 2025, Grifols reported its third-quarter financial results, highlighting a 9.1% year-over-year revenue increase to EUR 1,865 million, driven by the Biopharma business. The company achieved a group profit of EUR 127 million for the quarter, contributing to a 245% year-to-date profit increase. Grifols also improved its leverage ratio to 4.2x and maintained robust liquidity of EUR 1,475 million. The company continues to focus on free cash flow generation and strategic market positioning, with its immunoglobulin franchise showing significant growth.

The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.